APOA1 and atherosclerosis: Interestingly, the compelling evidence demonstrating the remarkable capacity of CER-001, an HDL-mimetic lipoprotein containing recombinant human ApoA-I, to enhance cholesterol mobilization, promote reverse cholesterol transport, and exhibit in vitro anti-inflammatory properties in an animal model of atherosclerosis suggests a strong potential for its efficacy in the treatment of septic conditions [46].